Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 0.99 |
| ▸ | PPP2CA | P67775 | 2/20 | 0.99 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.99 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.99 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.99 |
| ▸ | NPY4R | P50391 | 1/20 | 0.99 |
| ▸ | PPP2R5A | Q15172 | 1/20 | 0.99 |
| ▸ | MAPT | P10636 | 1/20 | 0.99 |
| ▸ | PPP6C | O00743 | 1/20 | 0.99 |
| ▸ | PPP5C | P53041 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Okadaic Acid SCHEMBL544727 | 1.00 | PPM1B (0.99) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL131485 | 0.99 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL22024950 | 0.99 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL21408784 | 0.99 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL24418495 | 0.99 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL23350437 | 0.99 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL2386832 | 0.99 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL17899362 | 0.99 | PPM1B (1.00) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL545397 | 0.99 | PPM1B (0.99) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 | |
| Okadaic Acid SCHEMBL4446706 | 0.99 | PPM1B (0.99) | PPM1BPPP2CAPTPN1PPP1CCTFPI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508249-B2 | Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxis | Cartesian Therapeutics Inc. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12472167-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity | CARTESIAN THERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4568750-A1 | COMPOSITIONS AND METHODS RELATED TO IMMUNOGLOBULIN PROTEASES AND FUSIONS THEREOF | Cartesian Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-12324826-B2 | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates | JOMOCO, CORP. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250177360-A1 | METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSE | CARTESIAN THERAPEUTICS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| EP-3858348-B1 | REPEATED ADMINISTRATION OF NON-IMMUNOSUPRESSIVE ANTIGEN SPECIFIC IMMUNOTHERAPEUTICS | CARTESIAN THERAPEUTICS INC (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-118987263-A | Methods and compositions for enhancing CD4+ regulatory T cells | 西莱克塔生物科技公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024229350-A1 | IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS FOR DIABETES | CARTESIAN THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024229380-A1 | IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS IN AUTOIMMUNE LIVER DISEASES | CARTESIAN THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024229370-A1 | COMPOSITIONS AND METHODS FOR TREATING GVHD | CARTESIAN THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| US-20220354947-A1 | METHODS FOR PROVIDING POLYMERIC SYNTHETIC NANOCARRIERS FOR GENERATING ANTIGEN-SPECIFIC TOLERANCE IMMUNE RESPONSES | SELECTA BIOSCIENCES, INC. (US) | 2022-11-10 | — | — | US | disclosed |
| US-20220323607-A1 | SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS TO ENHANCE IMMUNE TOLERANCE | SELECTA BIOSCIENCES, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| WO-2022217095-A1 | SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS TO ENHANCE IMMUNE TOLERANCE | SELECTA BIOSCIENCES, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022150335-A1 | VIRAL VECTOR DOSING PROTOCOLS | SELECTA BIOSCIENCES, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022098901-A1 | COMPOSITIONS FOR REDUCING IMMUNE RESPONSES AGAINST IMMUNOGLOBULIN PROTEASES | SELECTA BIOSCIENCES, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220133864-A1 | METHODS AND COMPOSITIONS FOR REDUCING IMMUNE RESPONSES AGAINST IMMUNOGLOBULIN PROTEASES | SELECTA BIOSCIENCES INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-11298342-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity | SELECTA BIOSCIENCES, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220071968-A1 | METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE | SELECTA BIOSCIENCES, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3962537-A1 | METHODS FOR TREATMENT OF SUBJECTS WITH PREEXISTING IMMUNITY TO VIRAL TRANSFER VECTORS | Selecta Biosciences, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| US-11235057-B2 | Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses | SELECTA BIOSCIENCES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133864-A1 | METHODS AND COMPOSITIONS FOR REDUCING IMMUNE RESPONSES AGAINST IMMUNOGLOBULIN PROTEASES | FCGR3B, SERPINB1, SERPINA6 | PPM1B 1444/4885PPP2CA 610/4885PTPN1 556/4885 |
| US-20250177360-A1 | METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSE | SERPINA6, FCGRT, FCGR3B | PPM1B 924/4885PPP2CA 882/4885PTPN1 326/4885 |
| US-11235057-B2 | Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses | CD47, LY96, CD74 | PPM1B 2644/4885PPP2CA 408/4885PTPN1 146/4885 |
| US-11298342-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity | CD74, HLA-DRB1, MSR1 | PPM1B 995/4885PPP2CA 509/4885PTPN1 367/4885 |
| US-20220354947-A1 | METHODS FOR PROVIDING POLYMERIC SYNTHETIC NANOCARRIERS FOR GENERATING ANTIGEN-SPECIFIC TOLERANCE IMMUNE RESPONSES | CD47, LY96, CD74 | PPM1B 2644/4885PPP2CA 408/4885PTPN1 146/4885 |
| US-20220071968-A1 | METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE | IL2, CD74, HLA-DRB1 | PPM1B 1513/4885PPP2CA 808/4885PTPN1 433/4885 |
| US-12508249-B2 | Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxis | HLA-C, CPA3, HLA-A | PPM1B 3087/4885PPP2CA 2397/4885PTPN1 272/4885 |
| US-12472167-B2 | Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity | CD74, CCR1, MSR1 | PPM1B 622/4885PPP2CA 635/4885PTPN1 230/4885 |
| US-20220323607-A1 | SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS TO ENHANCE IMMUNE TOLERANCE | IL2, IL2RA, ICOS | PPM1B 2829/4885PPP2CA 547/4885PTPN1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.